Metagenomi, Inc. Common Stock (MGX) - Total Liabilities
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has total liabilities worth $69.49 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Metagenomi, Inc. Common Stock (MGX) cash conversion ratio to assess how effectively this company generates cash.
Metagenomi, Inc. Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Metagenomi, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check Metagenomi, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Metagenomi, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Matriks Bilgi Dagitim Hizmetleri AS
IS:MTRKS
|
Turkey | TL264.43 Million |
|
Supra Boga Lestari Tbk
JK:RANC
|
Indonesia | Rp911.49 Billion |
|
Yooshin Engineering Corporation
KQ:054930
|
Korea | ₩184.07 Billion |
|
Annovis Bio Inc
NYSE:ANVS
|
USA | $4.03 Million |
|
Decibel Cannabis Company Inc
V:DB
|
Canada | CA$82.85 Million |
|
Ultimovacs ASA
OL:ULTI
|
Norway | Nkr33.19 Million |
|
Samhyun Steel Co. Ltd
KQ:017480
|
Korea | ₩23.14 Billion |
|
Societe de Tayninh SA
PA:TAYN
|
France | €86.44K |
Liability Composition Analysis (2021–2024)
This chart breaks down Metagenomi, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Metagenomi, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Metagenomi, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Metagenomi, Inc. Common Stock (2021–2024)
The table below shows the annual total liabilities of Metagenomi, Inc. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | $89.74 Million | -40.04% |
| 2023-09-30 | $149.67 Million | -69.39% |
| 2022-09-30 | $488.91 Million | +180.12% |
| 2021-09-30 | $174.54 Million | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration an… Read more